About US
Contact us
-
Bristol Myers' incoming CEO plots turnaround for struggling new launchesOn outgoing chief executive Giovanni Caforio’s last earnings call, Bristol Myers Squibb had some tough questions to answer about a roster of underperforming new products. But according to CEO-elect C2023/10/27
-
Amgen plans to lay off 350 former Horizon employees after $28B buyoutIn the biopharma industry, post-merger layoffs are often a question of when and how many. In the case of Amgen’s $27.8 billion buyout of Horizon, which wasrevealedlastDecember andfinalizedearlier thi2023/10/24
-
On heels of FDA approval, trial results set up GSK's RSV vaccine for label expansionFive months after becoming the first company to secure FDA approval for a respiratory syncytial virus (RSV) vaccine, GSK is taking steps toward expanding its label for Arexvy. On Wednesday, the compa2023/10/24
-
Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin useAfter several diabetic patients received a sham version of Roche's Avastin and lost their sight, the Drug Regulatory Authority of Pakistan (DRAP) is halting the sale or distribution of the drug until2023/10/19
-
GSK manufacturing review prompts Scynexis to pull Brexafemme, halt trials over contamination concernsWhen Scynexis won FDA approval for itsantifungal drug ibrexafungerp back in 2021, some analystspredictedthe drug could eventually surpass the $1 billion annual sales threshold. But now the drug's lau2023/10/19
-
Mission: Possible: Big Pharmas back star-fronted lung cancer awareness pushA who’s who of biopharma companies havebackeda push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate2023/10/17
-
Novartis targets first-line use for radiotherapy Lutathera after trial win in neuroendocrine tumorsMore than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple co-foun2023/10/17
-
Seagen and Astellas' Padcev, in Keytruda combo, delivers 'practice-changing' bladder cancer winAs Seagen prepares for its takeover by Pfizer, the company’s Astellas-partneredcancer drug Padcev has chalked up a key trial win—in combination with Merck's Keytruda—in previously untreated metastati2023/10/13
-
Look out, AZ. Lilly and Boehringer's Jardiance is ready to roll in chronic kidney disease after FDA nodFast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., to2023/10/13
-
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancerMerck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the2023/10/9